Company Overview of Humanigen, Inc.
Humanigen, Inc., a biopharmaceutical company, focuses on developing medicines for patients with neglected and rare diseases with focus on pediatric conditions in the United States. The company’s lead product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal, and neurological problems. It is also developing proprietary monoclonal antibodies, including lenzilumab, which is in Phase 1/2 clinical trial in patients with chronic myelomonocytic leukemia, and potentially for the treatment of juvenile myelomonocytic leukemia; and ifabotuzumab that has completed the Phase I dose escalation portion of a Phase I/II clinical tr...
1000 Marina Boulevard
Brisbane, CA 94005
Founded in 2000
Key Executives for Humanigen, Inc.
Chairman & CEO
Total Annual Compensation: $500.0K
Chief Scientific Officer
Total Annual Compensation: $427.5K
Compensation as of Fiscal Year 2016.
Humanigen, Inc. Key Developments
Humanigen, Inc. Appoints Greg Jester as Chief Financial Officer, Effective September 5, 2017
Aug 28 17
Humanigen, Inc. announced it has appointed Greg Jester as its chief financial officer (CFO), effective September 5, 2017. Mr. Jester brings more than two decades of financial, operational management and entrepreneurial experience in the life sciences industry. He will be responsible for further strengthening Humanigen’s financial foundation to facilitate the company’s next growth phase. Most recently, Mr. Jester served as vice president, finance, for Tris Pharma.
Humanigen, Inc. Announces Executive Changes
Aug 14 17
Humanigen, Inc. appointed Cameron Durrant as the Company's interim Chief Financial Officer, until a new Chief Financial Officer is in place. Dr. Durrant succeeds David L. Tousley, who resigned as the Company's interim Chief Financial Officer effective August 11, 2017.
Humanigen, Inc. Announces Completion of Benznidazole Bioavailability Study
Aug 8 17
Humanigen, Inc. announced that it has completed enrollment and follow-up of subjects in its human bioavailability study for benznidazole. The bioavailability study is a key part of the company’s planned New Drug Application (NDA) package to the U.S. Food and Drug Administration (FDA) in the 505(b)(2) development program for benznidazole as a potential treatment for Chagas disease, a neglected tropical disease. The study’s main objective is to characterize the pharmacokinetic profile of benznidazole. Analysis of the study has begun and the company anticipates preliminary interpretation of the data by October. The company expects to have the final study report in the fourth quarter of this year. The company expects to submit its NDA in the first quarter of 2018. The company received clearance from the FDA in June for its Investigational New Drug (IND) application and earlier this year received positive guidance from the FDA supporting the company’s proposed 505(b)(2) regulatory pathway for benznidazole, enabling the company to use data obtained from previously conducted studies to demonstrate safety and efficacy in the treatment of Chagas disease within the U.S.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 23, 2017
December 21, 2016